プラスチックフィルムへの香気成分の収着動態とその抑制に関する研究

第1章 緒論 第2章 プラスチック包材に対する香気成分収着関連因子測定法の確立 第3章 各種ポリエチレンフィルムへの香気成分の収着動態 第4章 香気成分の収着に及ぼす外的因子の影響と収着抑制因子の検索 第5章 保香性に優れた内面材フィルムの開発(I) : エチレン･酢酸ビニル共重合(EVA)フィルムに対する電子線照射 第6章 保香性に優れた内面材フィルムの開発(II) : 低密度ポリエチレン(LDPE)フィルムに対する電子線照射と収着抑制効果発現機構の解明 第7章 保香性に優れた内面材フィルムの開発(III) : LDPEフィルムへの極性基導入 第8章 総括Made available in DSpace on 2012-06-28T06:59:23Z (GMT). No. of bitstreams: 3 matsui1.pdf: 7330548 bytes, checksum: 51931f6eb70be0576256c9a4fec9f107 (MD5) matsui2.pdf: 11753768 bytes, checksum: 70c41f7a03de685e79d7fa654a5558af (MD5) matsui3.pdf: 10327288 bytes, checksum: 0ba4ac5bec2f09a8b89ea2b848944c6d (MD5) Previous issue date: 1991-03-27主1-参

Runge-Lenz Vector as a 3d Projection of SO(4) Moment Map in R4×R4\mathbb{R}^{4}\times\mathbb{R}^{4} Phase Space

We show, using the methods of geometric algebra, that Runge-Lenz vector in the Kepler problem is a 3-dimensional projection of SO(4) moment map that acts on the phase space of 4-dimensional particle motion. Thus, RL vector is a consequence of geometric symmetry of $\mathbb{R}^4\times \mathbb{R}^4$ phase space

Elevated levels of plasma lactate dehydrogenase is an unfavorable prognostic factor in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer, receiving treatment with gefitinib or erlotinib.

Treatment with epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) has been shown to prolong survival in patients with EGFR mutation-positive non-small cell lung cancer (NSCLC). The present study performed a retrospective analysis to investigate the association between the plasma lactate dehydrogenase (LDH) levels and survival in patients with EGFR mutation-positive NSCLC receiving treatment with EGFR-TKIs. The medical charts of patients with EGFR mutation-positive NSCLC who were receiving treatment with EGFR-TKIs at Toyama University Hospital between 2007 and 2014 were assessed. The data from 65 patients were included in the analysis. Patients with higher plasma LDH levels exhibited shorter progression-free survival (6.2 vs. 13.2 months; P<0.01) and overall survival (10.5 vs. 36.1 months; P<0.01) periods compared with patients with lower plasma LDH levels. A Cox proportional hazards model identified that the plasma LDH level was associated with the progression-free survival (P=0.05) and overall survival (P<0.01). An association was demonstrated between the pretreatment plasma LDH level and the survival in patients with EGFR mutation-positive NSCLC receiving treatment with EGFR-TKIs. Close observation is required in EGFR mutation-positive NSCLC patients exhibiting high plasma LDH levels following the initiation of treatment with EGFR-TKIs.出版社サイトへのリンク：https://doi.org/10.3892/mco.2016.77

Oral intake of rice overexpressing ubiquitin ligase inhibitory pentapeptide prevents atrophy in denervated skeletal muscle

We previously reported that intramuscular injections of ubiquitin ligase CBLB inhibitory pentapeptide (Cblin; Asp-Gly-pTyr-Met-Pro) restored lost muscle mass caused by sciatic denervation. Here, we detected Cblin on the basolateral side of Caco-2 cells after being placed on the apical side, and found that cytochalasin D, a tight junction opener, enhanced Cblin transport. Orally administered Cblin was found in rat plasma, indicating that intact Cblin was absorbed in vitro and in vivo. Furthermore, transgenic Cblin peptide-enriched rice (CbR) prevented the denervation-induced loss of muscle mass and the upregulation of muscle atrophy-related ubiquitin ligases in mice. These findings indicated that CbR could serve as an alternative treatment for muscle atrophy

Plasma neuron-specific enolase level as a prognostic marker in patients with non-small cell lung cancer receiving gefitinib.

Determination of the presence of epidermal growth factor receptor (EGFR) gene mutation is useful for predicting the efficacy of gefitinib. However, the survival rate following the initiation of treatment with gefitinib varies among individuals. A retrospective study was conducted to investigate the associations of the pretreatment serum pro-gastrin-releasing peptide (pro-GRP) and plasma neuron-specific enolase (NSE) levels to the patient survival rate following initiation of treatment with gefitinib in non-small cell lung cancer (NSCLC) patients receiving gefitinib treatment. Patients with NSCLC harboring EGFR gene mutations who received gefitinib therapy between 2004 and 2012 were included in the study. Data from a total of 41 patients were analyzed. The serum pro-GRP level was measured in 31 patients and the plasma NSE in 22 patients. The progression-free survival (PFS) (P=0.013) and overall survival (OS) (P=0.014, log-rank test) rates decreased as the plasma NSE level increased. Statistical analysis using a Cox proportional hazards regression model adjusted for age, gender, performance status (PS) and disease stage showed that higher NSE levels were associated with shorter PFS (P=0.021) and OS (P=0.0024). By contrast, no association was detected between the serum level of pro-GRP and survival rate. The results suggest that pretreatment NSE measurement could be clinically useful in patients with NSCLC scheduled to receive gefitinib treatment.出版社サイトへのリンク: https://doi.org/10.3892/mco.2015.56